Tech Company Financing Transactions

Viela Bio Funding Round

Viela Bio closed a $250 million Series A financing round on 3/1/2018. Backers included 6 Dimensions Capital, Boyu Capital and Hillhouse Capital Group.

Transaction Overview

Company Name
Viela Bio
Announced On
3/1/2018
Transaction Type
Venture Equity
Amount
$250,000,000
Round
Series A
Investors

6 Dimensions Capital (Lead Investor) (Leon Chen)

Boyu Capital (Lead Investor) (Yanling Cao)

Hillhouse Capital Group (Lead Investor) (Michael Yi)

Sirona Capital

Temasek Holdings

Proceeds Purpose
Viela Bio will use the proceeds from the initial financing to deliver the Phase II study of inebilizumab, efficiently develop the early-stage portfolio and continue exploring existing and novel pathways for next-generation inflammation and autoimmune therapy.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 MedImmune Way 5th Floor
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
www.vielabio.com
Email Address
[email protected]
Overview
Viela Bio (Nasdaq: VIE) is a biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
Profile
Viela Bio LinkedIn Company Profile
Social Media
Viela Bio Company Twitter Account
Company News
Viela Bio News
Facebook
Viela Bio on Facebook
YouTube
Viela Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Bing Yao
  Bing Yao LinkedIn Profile  Bing Yao Twitter Account  Bing Yao News  Bing Yao on Facebook
Chief Medical Officer
Jorn Drappa
  Jorn Drappa LinkedIn Profile  Jorn Drappa Twitter Account  Jorn Drappa News  Jorn Drappa on Facebook
VP - Bus. Development
William Ragatz
  William Ragatz LinkedIn Profile  William Ragatz Twitter Account  William Ragatz News  William Ragatz on Facebook
VP - Bus. Development
Aaron Ren
  Aaron Ren LinkedIn Profile  Aaron Ren Twitter Account  Aaron Ren News  Aaron Ren on Facebook
VP - Finance
Mitchell Chan
  Mitchell Chan LinkedIn Profile  Mitchell Chan Twitter Account  Mitchell Chan News  Mitchell Chan on Facebook
VP - Human Resources
Kate Surdez
  Kate Surdez LinkedIn Profile  Kate Surdez Twitter Account  Kate Surdez News  Kate Surdez on Facebook
VP - Marketing
Maureen Menacher
  Maureen Menacher LinkedIn Profile  Maureen Menacher Twitter Account  Maureen Menacher News  Maureen Menacher on Facebook
VP - Operations
Yang Wang
  Yang Wang LinkedIn Profile  Yang Wang Twitter Account  Yang Wang News  Yang Wang on Facebook
VP - Regulatory Affairs
Soraya Madani
  Soraya Madani LinkedIn Profile  Soraya Madani Twitter Account  Soraya Madani News  Soraya Madani on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/1/2018: Rubius Therapeutics venture capital transaction
Next: 3/1/2018: Eko venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.